Extent of coronary atherosclerotic disease (CAD) burden on coronary computed tomography angiography (CCTA) as measured by segment involvement score (SIS) has a prognostic value. We sought to investigate the incremental prognostic value of 'age adjusted SIS' (aSIS), which may be a marker of premature atherosclerosis and vascular age. Consecutive patients were prospectively enrolled into the CONFIRM (Coronary CT Angiography EvaluatioN For Clinical Outcomes: An InteRnational Multicentre) multinational observational study. Patients were followed for the outcome of all-cause death. aSIS was calculated on CCTA for each patient, and its incremental prognostic value was evaluated. A total of 22,211 patients [mean age 58.5 ± 12.7 years, 55.8% male) with a median follow-up of 27.3 months (IQR 17.8, 35.4)] were identified. After adjustment for clinical factors and presence of obstructive CAD, higher aSIS was associated with increased death on multivariable analysis, with hazard ratio (HR) 2.40 (1.83-3.16, p < 0.001), C-statistic 0.723 (0.700-0.756), net reclassification improvement (NRI) 0.36 (0.26-0.47, p < 0.001), and relative integrated discrimination improvement (IDI) 0.33 (p = 0.009). aSIS had HR 3.48 (2.33-5.18, p < 0.001) for mortality in those without obstructive CAD, compared to HR 1.79 (1.25-2.58, p = 0.02) in those with obstructive CAD. In conclusion, aSIS has an incremental prognostic value to traditional risk factors and obstructive CAD, and may enhance CCTA risk stratification.
Introduction
Coronary computed tomography angiography (CCTA) is recommended in symptomatic individuals for the detection and exclusion of coronary artery disease (CAD) [1] , and has a prognostic value [2] [3] [4] . Increasing extent of coronary atherosclerosis, as quantified by segment involvement score (SIS) or the synonymous total plaque score (TPS), has been shown to be a predictor of clinical events [5] [6] [7] . Rate of development of atherosclerotic disease has been shown to be a better predictor of adverse clinical outcomes [8] [9] [10] . Hence we devised a score 'age adjusted SIS' (aSIS), which standardizes SIS to the number of evaluable segments and normalizes it to patient age. We hypothesize that aSIS is a surrogate marker of 'vascular age', as it gives greater weighting to segments involved in those who are younger, and so may account for premature atherosclerotic disease.
Previous work demonstrated that aSIS (or as previously termed %TPS/age) had an incremental prognostic value over risk factors and obstructive CAD for MACE [11] . We sought to externally validate the prognostic value of aSIS in the large prospective multinational CONFIRM (COronary Computed Tomography Angiography Evaluation for Clinical Outcomes: An InteRnational Multicentre Registry) cohort.
Materials and methods

Study population
Consecutive patients undergoing CCTA were prospectively enrolled into the CONFIRM (COroNary CT Angiography Evaluation For Clinical Outcomes: An InteRnational Multicenter Registry). The design of the registry has been described in depth previously [12] . Inclusion criteria were adults (≥ 18 years) referred for clinically suspected CAD who underwent ≥ 64-detector row CCTA examination between February 2003 and September 2010 in twelve centers in six countries (Canada, Germany, Italy, Korea, Switzerland, and the United States). This study complies with the Declaration of Helsinki, and all centers had institutional review board approval for patient enrollment and follow-up. Only patients who provided informed consent were included.
Patients with a history of heart transplantation and congenital heart disease were excluded. To ensure there was no duplication of patients, we removed patients who had been analyzed in our previous study [11] . In addition, patients with < 11 segments reported (n = 6464) and patients who had missing information about clinical risk factors were removed from analysis. After excluding 7410 patients, a total of 22,211 patients were available for analysis (Fig. 1) .
Clinical data
Patient demographic data, medical history, risk factors, physical data, and indications for CCTA were collected before each CCTA examination in site-specific case report forms. Standardized definitions for cardiovascular risk factors were used [12] . National Cholesterol Education Program (NCEP) risk was calculated using age, gender, symptoms, and risk factors (smoking, hypertension, dyslipidemia, diabetes, and family history of premature CAD) [13] [14] [15] . 
CCTA image acquisition and analysis
CCTAs were performed with ≥ 64-detector row scanner, and included both single-source and dual-source scanners. Image acquisition, post-processing, and interpretation for CCTAs in the CONFIRM cohort were in compliance with each site's institutional policy or SCCT guidelines [12, 16] . CAC scores were calculated by the method of Agatston [17] . Standard post-processing techniques were used to determine the presence and extent of CAD, with obstructive CAD defined as a luminal diameter stenosis ≥ 50%. Coronary artery anatomy and the extent of atherosclerotic plaque were assessed using a 17-segment model of the coronary arteries (Fig. 2) [16] .
Calculation of aSIS
SIS was calculated as the total number of coronary segments with atherosclerotic plaque (irrespective of severity). aSIS was calculated as the quotient between SIS and the total number of segments that was evaluable for plaque, multiplied by 100, and adjusted by dividing by patient age (aSIS = ([SIS/total number of evaluable segments] × 100)/ age) (Fig. 2) . To obtain clinically applicable categorization, the cohort was divided into four categories of aSIS. All aSIS = 0 (no atherosclerosis) were assigned into the first category, and the remaining were divided into 3 categories based on cutoffs derived from our previous single-center study [11] .
Patient follow-up and outcome measure
All patients were followed for all-cause death, the pre-specified outcome for the CONFIRM registry, by local institutions through a dedicated physician or research nurse or both [12] . Death was ascertained by query of the National Death Index in US sites, and in non-US sites by direct interview or telephone contact with the patient's immediate family or primary physician or review of medical records [12] . As the National Death Index data do not include the cause of death, no data for cardiac death were available for analysis.
Statistical analysis
Absolute counts and percentages were presented for categorical variables, and continuous variables were presented as mean ± standard deviation (SD) for normally distributed data and medians [interquartile range (IQR)] for skewed data. The Wilcoxon rank sum test was used for continuous variables and Chi-square test for categorical variables. Univariable and multivariable analyses were [2, 5] , applying aSIS re-stratifies this younger patient into the highest risk category, suggesting more extensive CAD for age 1 3 performed to assess the prognostic value of aSIS for allcause death. Any risk factor or CT parameter that had statistically significant (p < 0.05) association for mortality on univariable analysis was included in the subsequent multivariable modeling. Cox proportional hazard models were performed for risk-adjusted analyses to evaluate the independent prognostic value of aSIS and construct adjusted survival curves. Statistically significant increases in the global Chi-square value and comparisons with global model fit using likelihood ratio tests were used to assess the incremental prognostic value of models with and without aSIS.
C-index of Harrell was assessed to determine the ability of models with aSIS to predict mortality [18] . Improvement in the prediction performance for mortality of a model that adds aSIS to clinical risk factors and presence of obstructive CAD was evaluated with the net reclassification improvement (NRI) index [19] . Category-free NRI which defines upward and downward movement as any change in the predicted probabilities was reported as a measure of discrimination with 95% confidence intervals, as it is not influenced by correct scaling of the model and is more generalizable [20] . The integrated discrimination improvement (IDI) and relative IDI were calculated to quantify the added predictive ability of models that included obstructive CAD and aSIS sequentially to clinical predictors. SAS Version 9.3 software (SAS Institute Inc., Cary, NC) was used to perform statistical calculations, with statistical significance defined as p < 0.05.
Results
Patient characteristics
A total of 22,211 patients (mean age 58.5 ± 12.7 years, 55.8% male) were identified with median follow-up time of 27.3 months (IQR 17.8, 35.4) ( Table 1 ). The follow-up rate for mortality was 96.5% in the CONFIRM cohort. Patients included in the analysis had a median aSIS of 0.16 (IQR 0.00, 0.47), and median SIS of 1.0 (IQR 0.0, 4.0). There was no visible coronary atherosclerosis (SIS and aSIS = 0) in 8763 (39.5%) patients.
Based on the previous work, patients were stratified into 4 categories (aSIS = 0, 0.001-0.314, 0.314-0.699, ≥ 0.700) [11] . Patients falling into, respectively, higher aSIS category had increasing rates of cardiovascular risk factors (diabetes, hypertension, hypercholesterolemia, smoking, and family history) and were more likely to be male (Table 1) . Additionally, those in the highest aSIS category (≥ 0.700) were more likely to have obstructive CAD (72%).
Clinical outcome
A total of 368 patients had the clinical outcome of death (Figs. 3, 4) . Forty-nine (0.6%) events were observed in the aSIS = 0 category (AER = 0.20%). 106 events (2.0%) were observed in the aSIS < 0.314 category (AER = 0.61%), 116 (2.3%) in the aSIS 0.314-0.699 category (AER = 0.78%), and 97 (3.2%) in the aSIS ≥ 0.700 category (AER = 1.08%) (Fig. 4) . Table 2 ). History of dyslipidemia and chest pain appeared to have lower mortality. In patients with dyslipidemia, this observation might be attributed to statin therapy. The protective nature of chest pain may be due to higher prevalence of non-cardiac chest pain, and treatment of symptomatic CAD with either optimal medical therapy or revascularization.
Univariable analysis
Number of segments with obstructive CAD (≥ 50% stenosis) was associated with HR 1.28 (1.23-1.33) for all-cause mortality, which was similar to, but slightly more predictive than that of SIS, with HR 1.22 (1.18-1.25), both p < 0.001. aSIS was most predictive of mortality with HR 3.68 (2.97-4.56), p < 0.001, followed by presence of obstructive CAD, with HR 3.11 (2.54-3.82), p < 0.001 (Table 2) . In subjects ≤ 50 years of age (n = 5702, 36 deaths) aSIS had HR 4.62 (2.62-8.15), whereas in those > 50 years old (n = 16,509, 332 deaths) HR was 3.22 (2.53-4.11), both p < 0.001.
Multivariable analysis
Cox proportional hazard modeling was performed to assess the prognostic value of aSIS over clinical predictors and obstructive CAD (Table 3) . aSIS had HR 2.40 (1.83-3.16) for all-cause death, p < 0.001, and Harrell C-statistic 0.723 (0.700-0.756) when applied in addition to clinical risk factors and obstructive CAD (≥ 50%). Use of aSIS category to predict all-cause death was associated with HR of 1.52 (1.36-1.71), p < 0.001 and Harrell C-statistic 0.735 (0.707-0.762).
Reclassification statistics
Category-free NRI was used to examine the ability of aSIS to appropriately reclassify patient risk for death. aSIS as a continuous variable had a category-free NRI of 0.36 (0.26-0.47), p < 0.001, for all-cause death when used 1 3 in addition to clinical predictors and obstructive CAD (Table 3) . IDI and relative IDI are also reported in Table 3 , and taken together, addition of obstructive CAD has a significant incremental reclassification effect over the model of clinical risk factors only, and the addition of aSIS has a further significant incremental reclassification effect over the model of clinical risk factors and obstructive CAD.
Higher aSIS category was also incremental over clinical predictors and obstructive CAD with NRI of 0.34 (0.24-0.44), p < 0.001. In 2 separate models used to compare 
Sub-analysis in patients with obstructive and non-obstructive CAD
aSIS was associated with highest risk for mortality, with highest hazard ratios for both patients with non-obstructive CAD and obstructive CAD (Tables 4, 5, 6 ). Importantly, in the population with non-obstructive CAD, aSIS had significantly higher HR for mortality than SIS or age alone.
Discussion
Using the CONFIRM registry, the independent and incremental prognostic value of aSIS was validated over routine clinical measures and CCTA measure of obstructive CAD. Higher aSIS categories were associated with increased risk of all-cause mortality (HR 2.40 (1.83-3.16), p < 0.001, and NRI of 0.36 (0.26-0.47), p < 0.01). Previous work demonstrated that aSIS (also termed %TPS/age) score has an incremental prognostic value for MACE over traditional risk factors and conventional CCTA assessment of coronary atherosclerosis [11] . We hypothesized that this novel measure, which can be quickly and easily derived from routine clinical CCTA, may be a surrogate marker of coronary vascular age. Although the prevalence of traditional risk factors and obstructive CAD increased with aSIS category, two-thirds of patients in the highest aSIS category had low or intermediate NCEP risk (Table 1) ; hence confirming the potential limitations of routine clinical risk predictors and the potential utility of aSIS to reclassify patient risk.
CCTA, extent of CAD, and prognosis
Framingham risk factors have only moderate correlation with atherosclerosis burden; a significant proportion of patients with low and intermediate Framingham risk have coronary atherosclerosis demonstrated by CCTA [21] . Anatomic evaluation of coronary arteries by CCTA allows early identification of coronary artery disease that may be subclinical and undetectable by functional testing, but is often the substrate of MACE [22, 23] . The presence of non-obstructive CAD on CCTA is associated with higher mortality even adjusting for CAD risk factors, with highest risk seen in those with greater extent of non-obstructive CAD [2, 4, 5] . SIS is a simple and reproducible semiquantitative measure quantifying the extent of CAD burden on CCTA (irrespective of degree of stenosis). Extent of CAD is a strong predictor of events [24] , and SIS ≥ 5 on CCTA has been shown to have worse prognosis that is comparable to the presence of obstructive CAD [2, 5] .
Coronary vascular age and atherosclerosis that is extensive for age
SIS and extent of CAD increase with age [25, 26] . Atherosclerosis begins in the early decades of life [27] , and may remain clinically silent for decades until plaque erosion and rupture result in clinical events or lesions become obstructive resulting in ischemia. However, individuals with more rapid development of coronary atherosclerosis have Fig. 4 Risk-adjusted survival curves by aSIS category, p < 0.001. aSIS = 0 category, whilst included in the continuous variable analysis, was not included in this figure as it was used as a reference for outcomes for the other aSIS categories an increased rate of adverse outcomes [8] [9] [10] 28] . Absolute plaque measurements may estimate 10-year risk which is independent of age; however, adjusting plaque burden to age gives a greater weighting for each involved segment if younger and may be a potential estimate of lifetime risk. For example, a 30-year-old and 60-year-old who have the same plaque burden and CAC theoretically may have the same 5-10 year risk; however, the 30-year-old would have atherosclerotic disease that has developed more rapidly and is more extensive for their age, and aSIS may act as a marker of vascular age and provide enhanced prediction of lifetime risk.
Clinical implications
The simplicity of SIS gives the potential for it to be calculated by automated software algorithms. Itss adjustment to age as aSIS may offer a method of enhanced risk stratification and prognostication by CCTA. With advancements in CT technology and novel scanning algorithms promising ongoing reduction in radiation dose and increasing use of CCTA, aSIS uses information readily available and easily calculable from clinical scans that may identify patients with 'greater vascular age' or atherosclerosis that is more extensive for age, and at greater risk of mortality. Additionally, aSIS may be a sensitive marker of subclinical (non-obstructive) disease, removing a false sense of security for some at-risk patients, and so improve adherence to preventative measures.
CT evaluation of coronary atherosclerosis impacts downstream testing and management, influences physician behavior, and results in better risk factor modification and increased medical therapy [29] [30] [31] . The use of statins has been associated with reduced risk for mortality in patients with non-obstructive disease on CCTA [32, 33] . Bittencourt et al. have shown that extent of plaque detected by CCTA enhances risk assessment, and even patients with nonobstructive disease and SIS > 4 had significant increase in events; it is thus possible that statins may reduce mortality in patients with higher aSIS [5] .
Whilst there is a lack of prospective data, aSIS could be a useful tool for triaging medical therapy. Further prospective studies are needed to understand the clinical role of aSIS, and potential economic benefits. However, findings from this study placed in the context of available CT data would suggest that higher aSIS warrants closer clinical surveillance and follow-up, and more aggressive institution of preventative measures including lifestyle modifications, more aggressive risk factor control, and consideration of statin therapy [5, 11, 29, 30, 33] .
Limitations
Ideally direct measures of plaque progression would provide us with information regarding true rates of change and how they may be attenuated with medical therapy. In the absence of such tests, aSIS may be a reasonable marker of premature atherosclerosis that is extensive for age. Age was removed from the multivariable analysis to avoid collinearity with aSIS, as age is part of the score; however, in the univariable analysis, aSIS score was a superior predictor of mortality than age, SIS or %SIS alone with much higher hazard ratios. Further studies are needed to better understand how such measures can be used to guide medical therapy. Although aSIS was prognostic for MACE in our previous study, not all CONFIRM centers were able to collect MACE. Therefore, all-cause mortality was the pre-specified primary end point for the CONFIRM registry [12] . Breakup of cause of death was not available from the query of the National Death Index for US sites.
Conclusion
aSIS may be a surrogate marker for vascular age and has independent and incremental prognostic value for all-cause mortality over traditional risk factors, obstructive CAD on CCTA. Further studies are needed to understand how it can be incorporated into clinical practice and how it might direct preventative measures.
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